BioFocus, a subsidiary of Galapagos NV, has signed a new drug discovery collaboration agreement with Ono Pharmaceutical Co. focused on discovering novel drugs for central nervous system disorders. Under the agreement, BioFocus will use its integrated drug discovery platform to deliver drug candidates and leads to Ono. The collaboration aims to strengthen Ono's drug discovery capabilities for CNS disorders with significant unmet medical needs. Financial details of the agreement were not disclosed.

1. +44 1799 533 500
info@glpg.com
Galapagos subsidiary BioFocus and Ono sign a drug discovery
agreement in the Field of CNS Disorders
Mon 03 Sep 2012
Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus and Ono
Pharmaceutical Co., Ltd. (Osaka Japan) have signed a new collaboration agreement, focused on
discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will
use its drug discovery platform to deliver leads and clinical candidates for its client. Financial
details were undisclosed.
“We are delighted to have this new agreement, which is the first drug discovery program with this,
a most valued, client” said Dr. Chris Newton, SVP Galapagos Services and Managing Director of
BioFocus. “This project plays to BioFocus historic strengths and the expanding breadth and depth
of this partnership is testament to a tried and trusted relationship.”
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive
Director, Discovery and Research of Ono commented: “We have the highest regard for the
BioFocus’ comprehensive drug discovery platform. This collaboration will strengthen Ono’s drug
discovery capability in the field of CNS disorders with significant unmet medical needs and we are
expecting that innovative drugs will be created through this collaboration.”
About BioFocus
BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all
therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases
and with a growing track record of delivering candidates against rare and neglected diseases.
BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client
projects to deliver targets, hits, leads and candidate pre-clinical drugs. The company employs over
250 exceptionally qualified and industry experienced scientists at its three research centers in the
UK, Switzerland and the Netherlands. Since its foundation in 1997, BioFocus has striven to
produce high quality data for its clients and this quality is assured by ISO9001 qualification
validated by regular, independent inspection of all BioFocus research centers.
About Galapagos

2. Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage biotechnology company
specialized in the discovery and development of small molecule and antibody therapies with novel
modes-of-action. The Company is progressing its JAK1 inhibitor GLPG0634, as well as one of the
largest pipelines in biotech, with four programs in development and over 30 discovery programs.
The Galapagos Group has about 800 employees and operates facilities in six countries, with
global headquarters in Mechelen, Belgium. More info at: www.glpg.com
About Ono
In keeping with its philosophy of “Dedicated to Man’s Fight against Disease and Pain,” Ono has
always striven to achieve its goal of serving as an R&D-oriented global specialty pharmaceuticals,
aiming to develop innovative and globally recognized drugs. To do this, Ono has been engaged in
drug discovery research based on accumulated technologies and know-how – in areas where its
strengths can be fully exploited (i.e. bioactive lipid agonists and enzyme inhibitors such as
proteases and kinases). In addition, modulators of membrane transport systems such as ion-
channels and transporters as well as biotechnology-based medicines are also the areas of our
focus where we drive forward our research effectively deploying our know-how from neuroscience
research and our gene assets together with the latest information acquired from global research
institutions on drug discovery targets and the cutting-edge drug discovery technologies that
biopharmaceutical companies can offer. For more information, please visit www.ono.co.jp.
Contact
Galapagos NV: Dr Chris Newton, SVP Galapagos Services Tel: +44 1799 533 535, Elizabeth
Goodwin, Director Investor Relations Tel: +31 62 291 6240 ir@glpg.com
This release may contain forward-looking statements, including, without limitation, statements
containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,”
“may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other factors which
might cause the actual results, financial condition, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.